4.7 Article

Drug-Drug Interactions among Patients Hospitalized with COVID-19 in Greece

期刊

JOURNAL OF CLINICAL MEDICINE
卷 11, 期 23, 页码 -

出版社

MDPI
DOI: 10.3390/jcm11237172

关键词

COVID-19; drug-drug interactions; SARS-CoV-2; pharmacotherapy; adverse drug reactions

向作者/读者索取更多资源

This study evaluated the prevalence and clinical significance of potential drug-drug interactions (DDIs) in COVID-19 patients admitted to a hospital in Greece. The results showed a high occurrence of DDIs in these patients, with clinically significant DDIs being associated with prolonged hospitalization. The study suggests that healthcare teams should address and resolve the additional burden of DDIs in COVID-19 patients.
The modulation of the pharmacological action of drugs due to drug-drug interactions (DDIs) is a critical issue in healthcare. The aim of this study was to evaluate the prevalence and the clinical significance of potential DDIs in patients admitted to the University Hospital of Heraklion in Greece with coronavirus disease 2019 (COVID-19). Cardiovascular disorders (58.4%) and diabetes (types I and II) (29.6%) were the most common comorbidities. A high occurrence of DDIs was observed, and clinically significant DDIs that may hamper response to treatment represented 40.3% of cases on admission, 21% during hospitalization, and 40.7% upon discharge. Polypharmacy and comorbidities were associated with a higher prevalence of DDIs in a statistically significant way (p < 0.05, 95% CI). Clinically significant DDIs and increased C-reactive protein values upon admission were associated with prolonged hospitalization. The results reveal that patients admitted due to COVID-19 in Greece often have an additional burden of DDIs that healthcare teams should approach and resolve.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据